We have located links that may give you full text access.
CASE REPORTS
JOURNAL ARTICLE
REVIEW
Technical approach of robotic total right hepatic lobectomy: How we do it?
Journal of Robotic Surgery 2019 April
Despite advantages of minimally invasive surgery, many hepatobiliary surgeons are hesitant to offer this approach for major hepatic resection due to concerns of difficulty in liver manipulation, bleeding control, and suboptimal oncologic outcomes. The robotic surgical system has revolutionized the way traditional laparoscopic liver resection is undertaken. Limitations of traditional laparoscopy are being resolved by robotic technology. We aimed to describe aspects of minimally invasive liver surgery and our standardized technical approach. We discussed technical aspects of performing robotic total right hepatic lobectomy and described our standardized institutional method. A 79-year-old man with an 11-cm biopsy-proven hepatocellular carcinoma was taken to the operating room for a robotic total right hepatic lobectomy. Past medical and surgical history was consistent with hypertension and diabetes mellitus. Robotic extrahepatic Glissonean pedicle approach was used to gain inflow vascular control. Right hepatic artery and portal vein were individually dissected and isolated prior to division. An intraoperative robotic ultrasound was utilized to guide liver parenchymal transection, securing negative margins. Robotic vessel sealing device was used as the main energy device during the parenchymal transection. Right hepatic vein was transected intrahepatically using a linear stapler. Operative time was 200 min without intraoperative complications. Estimated blood loss was 100 ml. Postsurgical recovery was uneventful and he was discharged home on postoperative day 4. Minimally invasive robotic total right hepatic lobectomy is feasible with excellent perioperative outcomes.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app